Dexonova EN 保護されたページ

Cell-free medicine

The power of cells, delivered without the cells.

Dexonova is a research-stage biotech company developing SHED-EV, exosomes released by stem cells from the pulp of baby teeth, as medicines. We are advancing programs in ophthalmology, immuno-oncology and systemic disease in Japan and the United States.

Dexonova K.K. was formerly named DEXON Pharmaceuticals Co., Ltd.

Technology

SHED-EV: one vesicle that acts on disease from two directions

SHED (stem cells from human exfoliated deciduous teeth) are stem cells obtained from the pulp of baby teeth that fall out naturally. We purify the exosomes from the culture medium of these cells and use the exosomes alone.

LEVER 1

Restoring proteostasis

SHED-EV captures destabilized proteins, supports their refolding and promotes the clearance of aggregated peptides. The aim is to stop the chain in which one aggregate seeds the next.

Areas: eye disease, systemic disease, neurodegeneration

LEVER 2

Improving the tumor microenvironment

SHED-EV suppresses the activation of cancer-associated fibroblasts (CAFs) and shifts tumor-supporting M2 macrophages toward tumor-attacking M1. It does not kill cancer cells directly. It prepares the ground for the host's own immunity to work.

Area: immuno-oncology

Cells of neural-crest origin

SHED derive from the neural crest and are rich in neurotrophic factors, which suits research on retinal and neural tissue.

No cells are administered

Because the product is cell-free, it avoids the tumorigenicity and rejection concerns of cell transplantation. It is also suited to standardization and storage.

Purified, not conditioned medium

We do not use the culture medium as it is. Exosomes are purified and tested for quality at our own cell processing facility.

Pipeline

Development pipeline

Ophthalmology leads, because the eye allows local delivery and has established endpoints. Immuno-oncology and systemic disease follow.

ProgramTarget and action DiscoveryNonclinicalPhase 1Phase 2

DEXON-EV-01Dry eye disease

Eye drop. Ocular surface inflammation and tear instability

Nonclinical

IMMUNO-ONCOLOGYTumor microenvironment-improving agent

CAF suppression and M2-to-M1 repolarization

Nonclinical (patented in Japan)

Cataract

Aggregation of lens crystallins

Discovery

Dry age-related macular degeneration

Amyloid-β in drusen

Discovery

Retinitis pigmentosa

Mutant rhodopsin and ER stress

Discovery

Post-infection and post-vaccination syndromes

Microclots formed by amyloid-type fibrin

Discovery

Neurodegenerative disease

Amyloid-β, tau and α-synuclein

Discovery

All programs are at the research and development stage. None has been approved as a medicine.

Research

Nonclinical results in the tumor microenvironment

Results of cell and animal studies described in our patent specification (JP 2026-7350 A).

Suppresses CAF activation

In human fibroblasts stimulated with TGF-β, expression of the CAF marker αSMA fell as the amount of SHED-EV increased.

Shifts macrophages toward M1

In human M2 macrophages, the M1 marker TNF-α rose and the M2 marker IL-10 fell.

Slows tumor growth in animals

In mice implanted with melanoma, the tumor signal 21 days after dosing was significantly lower than in the control group (P<0.05, 10 mice per group).

MICE WITHOUT IMMUNITY

No difference from control

In mice lacking T, B and NK cells, no difference was seen in the primary tumor or in metastases.

MICE WITH IMMUNITY

Tumor growth suppressed

The effect appears through the host's immune system. We are studying combination with immune checkpoint inhibitors.

These are results in animals and cells. Efficacy and safety in humans have not been established.

Intellectual property

Intellectual property

We pursue protection across composition, process and use.

10

granted patents

  • JP Patent No. 7946854 (application 2024-107076)

    Tumor microenvironment-improving agent

    A PCT application has been filed, with national phase entry planned in the US, Europe, China and Korea.

  • JP Patent No. 7220938 (application 2022-155607)

    NK cell activation, culture and production method

  • JP Patent No. 6894652 (application 2020-152115)

    Tissue repair agent, method of use and screening method

  • JP Patent No. 7007754 (application 2020-191759)

    Composition, binding inhibitor, medical device and method for preventing COVID-19

  • JP Patent No. 6974892 (application 2021-088875)

    Agent and method for improving cancer cachexia

  • JP Patent No. 6830286 (application 2020-110422)

    Agent and method for improving testicular (spermatogenic) function

  • JP Patent No. 6684956 (application 2019-220646)

    Cell proliferation method, cell proliferation agent and culture medium

  • JP Patent No. 7007770 (application 2021-102516)

    Agent and method for improving ocular symptoms

  • JP Patent No. 7492757 (application 2022-044972)

    Improvement of Alzheimer's disease and dementia

  • JP Patent No. 7720630 (application 2022-167247)

    Agent and method for improving erectile function (ED)

An application for a rejuvenation agent and rejuvenation method (JP 2025-32034 A) is pending. A foundational filing on proteostasis is in preparation.

Team

Team

Shoji Koga, M.D., Ph.D.

Founder & CEO, Dexonova K.K.
Chairman & CSO, Dexonova, Inc.

Physician. Vice Director of Edogawa Hospital. Board-certified in urology, transplantation, regenerative medicine and dialysis. Researched cancer gene therapy at the Cleveland Clinic from 1996 to 1999.

Takahiro Ochiya, Ph.D.

Co-Founder & Scientific Advisor

Professor, Tokyo Medical University; formerly at the National Cancer Center Research Institute. A leading researcher in extracellular vesicles and a seven-time Highly Cited Researcher.

Doug Arm, Ph.D.

President, Dexonova, Inc.

Leads the US company, with responsibility for development strategy toward an FDA IND and for commercialization. Formerly of Cytori Therapeutics.

News

News

Company

Company

Name
Dexonova K.K.
Formerly DEXON Pharmaceuticals Co., Ltd.
Representative
Shoji Koga, Founder & CEO
Address
Ginza Willow Avenue BLDG 5F, 1-5-8 Ginza, Chuo-ku, Tokyo, Japan
Business
Research and development of medicines based on exosomes from stem cells of human exfoliated deciduous teeth (SHED-EV), and management of related intellectual property
US company
Dexonova, Inc. (Delaware, USA)
Contact
[Contact email address]